Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - A real-world population study in Taiwan

International Journal of Cardiology

Volumn 215, Issue , 2016, Pages 114-119

  Pai, Pei Ying ^a   Muo, Chih Hsin ^b   Sung, Fung Chang ^a,b   Ho, Hung Chi ^a   Lee, Yuan Teh ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

CV risk; RAAS; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; RAMIPRIL; TELMISARTAN; VALSARTAN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEALTH INSURANCE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; TAIWAN; ADOLESCENT; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; FEMALE; FOLLOW UP; HEALTH SURVEY; MALE; MIDDLE AGED; PROCEDURES; STROKE; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRAIN ISCHEMIA; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; STROKE; TAIWAN; YOUNG ADULT;

EID: 84964324456     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.04.096     Document Type: Article

References (32)

1. J.D. Neaton, and D. Wentworth Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple risk factor intervention trial research group Arch. Intern. Med. 152 1 1992 56 64
2. UKPDS Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group BMJ 317 7160 1998 703 713
3. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., and et al. The seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report J. Am. Med. Assoc. 289 19 2003 2560 2572
4. M. Ezzati, A.D. Lopez, A. Rodgers, S. Vander Hoorn, and C.J. Murray Selected major risk factors and global and regional burden of disease Lancet 360 9343 2002 1347 1360
5. Taiwan Guidelines for the Management of Stroke 2008. ISBN: 978-986-84829-0-6. 2008.
6. B. Neal, S. MacMahon, and N. Chapman Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood pressure lowering treatment Trialists' collaboration Lancet 356 9246 2000 1955 1964
7. F. Turnbull Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 362 9395 2003 1527 1535
8. A. Holdiness, K. Monahan, D. Minor, and R.D. de Shazo Renin angiotensin aldosterone system blockade: little to no rationale for ACE inhibitor and ARB combinations Am. J. Med. 124 1 2011 15 19
9. L.H. Lindholm, L. Hansson, T. Ekbom, B. Dahlof, J. Lanke, E. Linjer, and et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish trial in old patients with hypertension-2. STOP hypertension-2 study group J. Hypertens. 18 11 2000 1671 1675
10. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 23) 2002 2981 2997
11. B. Dahlof, P.S. Sever, N.R. Poulter, H. Wedel, D.G. Beevers, M. Caulfield, and et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial Lancet 366 9489 2005 895 906
12. J. Bosch, E. Lonn, J. Pogue, J.M. Arnold, G.R. Dagenais, and S. Yusuf Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension Circulation 112 9 2005 1339 1346
13. B. Dahlof, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, and et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol Lancet 359 9311 2002 995 1003
14. S. Julius, S.E. Kjeldsen, M. Weber, H.R. Brunner, S. Ekman, L. Hansson, and et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial Lancet 363 9426 2004 2022 2031
15. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, and et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N. Engl. J. Med. 345 12 2001 851 860
16. B.M. Psaty, T. Lumley, C.D. Furberg, G. Schellenbaum, M. Pahor, M.H. Alderman, and et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis J. Am. Med. Assoc. 289 19 2003 2534 2544
17. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2007 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J. Hypertens. 25 6 2007 83
18. M. Tokmakova, and S.D. Solomon Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials Curr. Opin. Cardiol. 21 4 2006 268 272
19. J.F. Mann, R.E. Schmieder, M. McQueen, L. Dyal, H. Schumacher, J. Pogue, and et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial Lancet 372 9638 2008 547 553
20. S. Yusuf, K.K. Teo, J. Pogue, L. Dyal, I. Copland, H. Schumacher, and et al. Telmisartan, ramipril, or both in patients at high risk for vascular events N. Engl. J. Med. 358 15 2008 1547 1559
21. Linda F. Fried, Nicholas Emanuele, and Jane H. Zhang for the VA NEPHRON-D Investigators Combined angiotensin inhibition for the treatment of diabetic nephropathy N. Engl. J. Med. 369 2013 1892 1903
22. NHI profile (updated 2009.06.05). 2009.
23. G. Reboldi, F. Angeli, C. Cavallini, G. Gentile, G. Mancia, and P. Verdecchia Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: A meta-analysis J. Hypertens. 26 7 2008 1282 1289
24. H. Lithell, L. Hansson, I. Skoog, D. Elmfeldt, A. Hofman, B. Olofsson, and et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial J. Hypertens. 21 5 2003 875 886
25. Harikrishna Makani, Sripal Bangalore, Kavit A. Desouza, Arpit Shah, and Franz H. Messerli Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials BMJ 346 2013 f360
26. P.H. Liu, and J.D. Wang Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan BMC Health Serv. Res. 8 2008 133
27. C.C. Chou, M.S. Lee, C.H. Ke, and M.H. Chung Prescription patterns of hypertension-National Health Insurance in Taiwan J. Chin. Med. Assoc. 67 3 2004 123 130
28. E.L. Schiffrin, J.B. Park, H.D. Intengan, and R.M. Touyz Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan Circulation 101 14 2000 1653 1659
29. J.S. Healey, A. Baranchuk, E. Crystal, C.A. Morillo, M. Garfinkle, S. Yusuf, and et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis J. Am. Coll. Cardiol. 45 11 2005 1832 1839
30. J.B. Park, H.D. Intengan, and E.L. Schiffrin Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension J. Renin-Angiotensin-Aldosterone Syst. 1 1 2000 40 45
31. A. Ido, N. Hasebe, T. Takeuchi, and K. Kikuchi Effects of temocapril and olmesartan on myocardial sympathetic nervous activity and fatty acid metabolism in rats with chronic beta-adrenergic stimulation J. Cardiovasc. Pharmacol. 41 Suppl. 1 2003 S133 S137
32. K. Yamaguchi, N. Ura, H. Murakami, N. Togashi, M. Hyakukoku, K. Higashiura, and et al. Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-alpha and cyclic AMP in skeletal muscle Hypertens. Res. 28 9 2005 773 778